SAK3 is a potent enhancer of T-type calcium channel activity, particularly Cav3.1 channels, and has shown promise in neuropharmacological research. It is primarily investigated for its cognitive-enhancing and neuroprotective properties. Studies indicate that SAK3 promotes the release of acetylcholine in the brain, which plays a critical role in learning and memory, making it a candidate for the treatment of neurodegenerative disorders such as Alzheimer’s disease.

In preclinical models, SAK3 has demonstrated the ability to reduce amyloid-beta accumulation and improve memory deficits. It also shows antidepressant-like effects and may help regulate sleep-wake cycles by modulating neuronal excitability in the thalamus. Due to its ability to enhance slow-wave sleep and support cholinergic function, SAK3 is being explored as a therapeutic agent for sleep disorders and cognitive impairments associated with aging and neurological diseases. Its small molecule structure allows for good blood-brain barrier penetration, which supports its potential for oral administration in future clinical applications.